Post by Tony Crispino on Dec 21, 2013 15:31:18 GMT -8
Last week the CHAARTED study results were published:
Reference: E3805: CHAARTED: ChemoHormonal Therapy Versus Androgen Ablation Randomized Trial for Extensive Disease in Prostate Cancer. The full protocol for this trial can be found at clinicaltrials.gov/ct2/show/NCT00309985.
Currently it is not clear how all current trials out there for these patients will be affected. There are many trials out there that are testing Enzalutamide, Abiraterone Acetate, TAK700 and more in this setting. At SWOG there has been special session to discuss though no official modifications have been made. But it is quite possible that many trials may face recall or modification to allow for chemotherapy early. Of course trials are still needed to see if there is a better approach than docetaxel as it is rich in side effects. What happens moving forward will be interesting.
Tony
Reference: E3805: CHAARTED: ChemoHormonal Therapy Versus Androgen Ablation Randomized Trial for Extensive Disease in Prostate Cancer. The full protocol for this trial can be found at clinicaltrials.gov/ct2/show/NCT00309985.
Currently it is not clear how all current trials out there for these patients will be affected. There are many trials out there that are testing Enzalutamide, Abiraterone Acetate, TAK700 and more in this setting. At SWOG there has been special session to discuss though no official modifications have been made. But it is quite possible that many trials may face recall or modification to allow for chemotherapy early. Of course trials are still needed to see if there is a better approach than docetaxel as it is rich in side effects. What happens moving forward will be interesting.
Tony
